Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Will AbbVie (ABBV) Disappoint This Earnings Season? - Analyst Blog
Will Eli Lilly (LLY) Keep Its Earnings Streak Alive? - Analyst Blog
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)
Related NVS
Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns
RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis
Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk (Fox Business)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Most Popular

Related Articles (TEVA + NVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free